Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Maria Pitsiu"'
Autor:
Maria Pitsiu, Özkan Yalkinoglu, Colm Farrell, Pascal Girard, Cristina Vazquez‐Mateo, Orestis Papasouliotis
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1157-1169 (2023)
Abstract B cell stimulating factor (BLyS) and a proliferation‐inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRI
Externí odkaz:
https://doaj.org/article/9efaa86ce0bd41dbb6749afefe027a5e
Autor:
Brian M. Sadler, Franck Skobieranda, Maria Pitsiu, Colm Farrell, Michael J. Fossler, David A. Burt, David G. Soergel
Publikováno v:
The Journal of Clinical Pharmacology. 58:762-770
Oliceridine is a novel G protein-biased ligand at the μ-opioid receptor that differentially activates G protein coupling while mitigating β-arrestin recruitment. Unlike morphine, oliceridine has no known active metabolites; therefore, analgesic eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa55d61d3a3d0dc7c9c5c3e2ff6b8388
https://doi.org/10.1002/jcph.1075
https://doi.org/10.1002/jcph.1075
Autor:
Brian M. Sadler, David A. Burt, David G. Soergel, Franck Skobieranda, Maria Pitsiu, Michael J. Fossler, Colm Farrell
Publikováno v:
Journal of clinical pharmacology. 58(6)
Conventional opioids bind to μ-opioid receptors and activate 2 downstream signaling pathways: G-protein coupling, linked to analgesia, and β-arrestin recruitment, linked to opioid-related adverse effects and limiting efficacy. Oliceridine (TRV130)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d005f52612a8ba052d4f0efe2141872c
https://pubmed.ncbi.nlm.nih.gov/29412458
https://pubmed.ncbi.nlm.nih.gov/29412458
Autor:
Max Lataillade, Malaz Abu Tarif, Li Zhu, Samit R Joshi, Matthew Hruska, Ishani Savant Landry, Maria Pitsiu, David W. Boulton, George J. Hanna, Richard Bertz, Brian M. Sadler
BMS-663068 is an oral prodrug of the HIV-1 attachment inhibitor BMS-626529, which prevents viral attachment to host CD4 + T cells by binding to HIV-1 gp120. To guide dose selection for the phase 3 program, pharmacokinetic/pharmacodynamic modeling was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7631a914f6e2710b43450e5a8181891b
https://europepmc.org/articles/PMC4862460/
https://europepmc.org/articles/PMC4862460/
Publikováno v:
British Journal of Clinical Pharmacology. 57:402-411
Aims To evaluate retrospectively the population pharmacokinetics of cetirizine, a second-generation antihistamine, in children. Methods Data were pooled from six clinical trials, in which cetirizine was administered orally in various formulations and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb13fd3af6467e1d7458ab3bdc720d11
https://doi.org/10.1046/j.1365-2125.2003.02017.x
https://doi.org/10.1046/j.1365-2125.2003.02017.x
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 29:49-66
In this modeling study we utilize previously published nicotine pharmacokinetic (PK) and pharmacodynamic (PD, heart rate) data to investigate the influence of PK sampling site (venous vs. arterial) on the selection of a specific PD tolerance model an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44f706742343fc92be9c3df85ba5005f
https://doi.org/10.1023/a:1015768602037
https://doi.org/10.1023/a:1015768602037
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 29:383-402
Significant arterio-venous differences in nicotine concentrations have been observed during and after cigarette smoking, nicotine nasal spray, and intravenous nicotine administration. In this paper we describe a novel mathematical method for estimati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdc2632147724d6ff612b8b7dee671e3
https://doi.org/10.1023/a:1020957208071
https://doi.org/10.1023/a:1020957208071
Publikováno v:
Journal of Pharmaceutical Sciences. 90:702-712
In vitro–in vivo correlation (IVIVC) models may be used to predict in vivo drug concentration–time profiles given in vitro release characteristics of a drug. This prediction is accomplished by incorporating in vitro release characteristics as an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c631e5d795d2c129e26cf19b882257d1
https://doi.org/10.1002/jps.1026
https://doi.org/10.1002/jps.1026
Publikováno v:
Clinical Therapeutics. 22:1494-1501
Background: Citalopram and theophylline may be prescribed together to treat patients with depression and asthmatic disease. Because theophylline has a low therapeutic index, small changes in plasma levels may result in therapeutic failure or adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d581ad57223c18b9b38c73c637c5c5
https://doi.org/10.1016/s0149-2918(00)83047-7
https://doi.org/10.1016/s0149-2918(00)83047-7
Publikováno v:
British journal of anaesthesia. 107(3)
Background The aim was to characterize ropivacaine and 2′,6′-pipecoloxylidide (PPX) pharmacokinetics and factors affecting them in paediatric anaesthesia. Methods Population pharmacokinetics of ropivacaine and its active metabolite PPX were estim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32670477a2d3caf67242fd22a95c412a
https://pubmed.ncbi.nlm.nih.gov/21693469
https://pubmed.ncbi.nlm.nih.gov/21693469